NVCR
HOLD / NEUTRALMeanRevComposite
46.40
Technical
68.20
Fundamental
39.20
Rank
—
Price
17.03
Hurst
0.12
As of
Jul 28, 2026
Daily
NovoCure Limited
HealthcareMedical DevicesNovoCure Limited is an oncology company that develops and sells medical devices using tumor treating fields technology to address solid malignancies across multiple markets including North America, Europe, and Asia. The company's product portfolio encompasses several Optune devices designed for different applications, with additional research programs exploring effectiveness against various cancer types such as brain, gastric, liver, and pancreatic cancers. Founded in 2000 and based in Switzerland, the company manufactures and distributes these therapies internationally.
Market cap
$1.5B
P/E (trailing)
—
P/E (forward)
-16.97
PEG ratio
—
Dividend yield
0.00%
Beta
0.99
52w range
9.82 – 21.45
Return on equity
-35.19%
Profit margin
-16.78%
Revenue growth
+15.70%
Earnings growth
—
Price history
1Y: 13.15 (+2.6%) · range 10.03–19.99
Cycle position
30/ 100 cycle scoreAPPROACHING ENTRY
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 69 · GOOD SETUP · exit proximity 0
Conviction
54/ 100 · maturity 14%
VScore.0917
Buildup.3056
EMA entry setup.3869
Fundamentals.2339
Volume profile
POC
17.51
Price vs POC
-24.9%
Overhead supply
97%
Runway
+21.5%
Value area 14.92–18.38 · 97% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.967 | Oct 30, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +8.03% | +11.59% | mature |
| 40d | -0.37% | +11.59% | mature |